البلد: أيرلندا
اللغة: الإنجليزية
المصدر: HPRA (Health Products Regulatory Authority)
AMFEBUTAMONE HYDROCHLORIDE
PCO Manufacturing
150 Milligram
Tablets
2002-09-13
IRISH MEDICINES BOARD ACTS 1995 AND 2006 MEDICINAL PRODUCTS(CONTROL OF PLACING ON THE MARKET)REGULATIONS,2007 (S.I. NO.540 OF 2007) PPA0465/089/001A Case No: 2058942 The Irish Medicines Board in exercise of the powers conferred on it by the above mentioned Regulations hereby grants to PCO MANUFACTURING LIMITED UNIT 10, ASHBOURNE BUSINESS PARK, RATH, ASHBOURNE, CO. MEATH, IRELAND an authorisation, subject to the provisions of the said Regulations, in respect of the product ZYBAN 150 MG PROLONGED RELEASE TABLETS The particulars of which are set out in Part I and Part II of the attached Schedule. The authorisation is also subject to the general conditions as may be specified in the said Regulations as listed on the reverse of this document. This authorisation, unless previously revoked, shall continue in force from 09/12/2008. Signed on behalf of the Irish Medicines Board this ________________ A person authorised in that behalf by the said Board. IRISH MEDICINES BOARD ________________________________________________________________________________________________________________________ _Date Printed 09/12/2008_ _CRN 2058942_ _page number: 1_ PART II SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Zyban 150 mg Prolonged Release Tablets. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains bupropion hydrochloride 150mg. For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Prolonged Release Tablet _Product sourced from Belgium and the United Kingdom_. White, film-coated, biconvex, round tablet, printed on one side with ‘GX CH7’ and plain on the other side. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Zyban tablets are indicated as an aid to smoking cessation in combination with motivational support in nicotine- dependent patients. 4.2 POSOLOGY AND ME اقرأ الوثيقة كاملة